Skip to main content
SpringerLink
Log in

Clinical outcomes of gemtuzumab ozogamicin for relapsed acute myeloid leukemia: single-institution experience

  • Original Article
  • Published:
International Journal of Hematology Aims and scope Submit manuscript

Abstract

We retrospectively evaluated the clinical efficacy and toxicity of gemtuzumab ozogamicin (GO) in patients with relapsed acute myeloid leukemia (AML). Nineteen patients (median 70 years) received GO (9 mg/m2, days 1 and 15) as salvage therapy in our institution between 2006 and 2017. The primary endpoint was the response rate. The secondary endpoint was the occurrence of adverse events. Thirteen patients had de novo AML, and 6 patients had secondary AML. Most of the patients had received salvage treatments more than once prior to GO. Six patients responded to the treatment (31.6%) with 3 complete remissions (15.8%). Five patients had stable disease, and 8 patients did not show any response. GO was more efficacious among the patients with fewer numbers of prior salvage treatments. CD33 positivity of leukemic cells was higher in responders than in nonresponders. Peripheral WT1 mRNA levels mostly decreased over time in the responders. The adverse event most commonly seen was febrile neutropenia (84%). No patient presented with veno-occlusive disease. Three patients died by day 30 (mortality rate 15.8%), one due to acute respiratory distress syndrome and the other two due to sepsis. GO remains an effective salvage treatment.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5

Similar content being viewed by others

References

  1. Short NJ, Rytting ME, Cortes JE. Acute myeloid leukaemia. Lancet. 2018;392:593–606.

    Article  Google Scholar 

  2. Kassim AA, Savani BN. Hematopoietic stem cell transplantation for acute myeloid leukemia: a review. Hematol Oncol Stem Cell Ther. 2017;10:245–51.

    Article  CAS  Google Scholar 

  3. Ohtake S, Miyawaki S, Fujita H, Kiyoi H, Shinagawa K, Usui N, et al. Randomized study of induction therapy comparing standard-dose idarubicin with high-dose daunorubicin in adult patients with previously untreated acute myeloid leukemia: the JALSG AML201 Study. Blood. 2011;117:2358–65.

    Article  CAS  Google Scholar 

  4. Miyawaki S, Ohtake S, Fujisawa S, Kiyoi H, Shinagawa K, Usui N, et al. A randomized comparison of 4 courses of standard-dose multiagent chemotherapy versus 3 courses of high-dose cytarabine alone in postremission therapy for acute myeloid leukemia in adults: the JALSG AML201 Study. Blood. 2011;117:2366–72.

    Article  CAS  Google Scholar 

  5. DeStefano CB, Hourigan CS. Personalizing initial therapy in acute myeloid leukemia: incorporating novel agents into clinical practice. Ther Adv Hematol. 2018;9:109–21.

    Article  CAS  Google Scholar 

  6. Bross PF, Beitz J, Chen G, Chen XH, Duffy E, Kieffer L, et al. Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia. Clin Cancer Res. 2001;7:1490–6.

    CAS  PubMed  Google Scholar 

  7. Petersdorf SH, Kopecky KJ, Slovak M, Willman C, Nevill T, Brandwein J, et al. A phase 3 study of gemtuzumab ozogamicin during induction and postconsolidation therapy in younger patients with acute myeloid leukemia. Blood. 2013;121:4854–60.

    Article  CAS  Google Scholar 

  8. Castaigne S, Pautas C, Terré C, Raffoux E, Bordessoule D, Bastie JN, et al. Acute Leukemia French Association. Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study. Lancet. 2012;379:1508–16.

    Article  CAS  Google Scholar 

  9. Lambert J, Pautas C, Terré C, Raffoux E, Turlure P, Caillot D, et al. Gemtuzumab ozogamicin for de novo acute myeloid leukemia: final efficacy and safety updates from the open-label, phase 3 ALFA-0701 trial. Haematologica. 2019;104:113–9.

    Article  CAS  Google Scholar 

  10. Burnett AK, Hills RK, Milligan D, Kjeldsen L, Kell J, Russell NH, et al. Identification of patients with acute myeloblastic leukemia who benefit from the addition of gemtuzumab ozogamicin: results of the MRC AML 15 trial. J Clin Oncol. 2010;29:369–3677.

    Article  Google Scholar 

  11. Burnett AK, Russell NH, Hills RK, Kell J, Freeman S, Kjeldsen L, et al. Addition of gemtuzumab ozogamicin to induction chemotherapy improves survival in older patients with acute myeloid leukemia. J Clin Oncol. 2012;30:3924–31.

    Article  CAS  Google Scholar 

  12. Chantepie SP, Reboursiere E, Mear JB, Gac AC, Salaun V, Benabed K, et al. Gemtuzumab ozogamicin in combination with intensive chemotherapy in relapsed or refractory acute myeloid leukaemia. Leuk Lymphoma. 2015;56:2326–30.

    Article  CAS  Google Scholar 

  13. Kharfan-Dabaja MA, Hamadani M, Reljic T, Pyngolil R, Komrokji RS, Lancet JE, et al. Gemtuzumab ozogamicin for treatment of newly diagnosed acute myeloid leukaemia: a systematic review and meta-analysis. Brit J Haematol. 2013;163:315–25.

    Article  CAS  Google Scholar 

  14. Jen EY, Ko CW, Lee JE, Del Valle PL, Aydanian A, Jewell C, et al. FDA Approval: gemtuzumab ozogamicin for the treatment of adults with newly diagnosed CD33-positive acute myeloid leukemia. Clin Cancer Res. 2018;24:3242–6.

    Article  CAS  Google Scholar 

  15. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology Acute Myeloid Leukemia Version 2. 2018. http://www.nccn.org/professionals/physician_gls/PDF/aml.pdf. Accessed 01 Aug 2018.

  16. Cheson BD, Bennett JM, Kopecky KJ, Büchner T, Willman CL, Estey EH, et al. International working group for diagnosis, standardization of response criteria, treatment outcomes, and reporting standards for therapeutic trials in acute myeloid leukemia. Revised recommendations of the international working group for diagnosis, standardization of response criteria, treatment outcomes, and reporting standards for therapeutic trials in acute myeloid leukemia. J Clin Oncol. 2003;21:4642–9.

    Article  Google Scholar 

  17. Miyawaki S, Hatsumi N, Tamaki T, Naoe T, Ozawa K, Kitamura K, et al. Prognostic potential of detection of WT1 mRNA level in peripheral blood in adult acute myeloid leukemia. Leuk Lymphoma. 2010;51:1855–61.

    Article  CAS  Google Scholar 

  18. O’Dwyer K, Freyer DR, Horan JT. Treatment strategies for adolescent and young adult patients with acute myeloid leukemia. Blood. 2018;132:362–8.

    Article  Google Scholar 

  19. Sievers EL, Larson RA, Stadtmauer EA, Estey E, Löwenberg B, Dombret H, Mylotarg study group, et al. Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse. J Clin Oncol. 2001;19:3244–54.

    Article  CAS  Google Scholar 

  20. Kobayashi Y, Tobinai K, Takeshita A, Naito K, Asai O, Dobashi N, et al. Phase I/II study of humanized anti-CD33 antibody conjugated with calicheamicin, gemtuzumab ozogamicin, in relapsed or refractory acute myeloid leukemia: final results of Japanese multicenter cooperative study. Int J Hematol. 2009;89:460–9.

    Article  CAS  Google Scholar 

  21. Yamaguchi Y, Usui N, Dobashi N, Yano S, Yahagi Y, Takei Y, et al. Gemtuzumab ozogamicin (GO) in relapsed/refractory patients with acute myeloid leukemia. Gan To Kagaku Ryoho. 2009;36:1105–9.

    PubMed  Google Scholar 

  22. Hanbali A, Wollner I, Neme K, Ulreich C. Fatal hypersensitivity reaction to gemtuzumab ozogamicin associated with platelet transfusion. Am J Health Syst Pharm. 2007;64:1401–2.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Hematology and Oncology, University of Fukui, 23-3, Shimoaizuki, Fukui, Matsuoka, 910-1193, Japan

    Naoko Hosono, Miyuki Ookura, Hiroaki Araie, Mihoko Morita, Kazuhiro Itoh, Yasufumi Matsuda & Takahiro Yamauchi

Authors
  1. Naoko Hosono
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Miyuki Ookura
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Hiroaki Araie
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Mihoko Morita
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Kazuhiro Itoh
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Yasufumi Matsuda
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Takahiro Yamauchi
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Naoko Hosono.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Hosono, N., Ookura, M., Araie, H. et al. Clinical outcomes of gemtuzumab ozogamicin for relapsed acute myeloid leukemia: single-institution experience. Int J Hematol 113, 362–369 (2021). https://doi.org/10.1007/s12185-020-03023-4

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12185-020-03023-4

Keywords

Search

Navigation